Drugmakers File Emergency Supreme Court Appeal to Restore Mifepristone Access by Mail

On May 1, 2026, the U.S. Court of Appeals for the 5th Circuit issued an order that, by the court's own admission, would "as a practical matter, have a nationwide effect" [1]. The ruling reinstated a requirement that mifepristone — the first drug in a two-pill medication abortion regimen used in approximately 65% of all U.S. abortions — be dispensed only in person, reversing FDA rules that had permitted telehealth prescriptions and mail-order pharmacy delivery since 2021 [2][3].

One day later, Danco Laboratories, the brand-name manufacturer of Mifeprex, filed an emergency application at the Supreme Court asking the justices to stay the 5th Circuit's order while the case continues [4]. GenBioPro, the sole generic mifepristone manufacturer in the United States, joined the effort, warning that the ruling "injects immediate confusion and upheaval into highly time-sensitive medical decisions" [5].

The case — Louisiana v. FDA — marks the second time in three years that the Supreme Court has been asked to weigh in on mifepristone access. But unlike the 2024 challenge in FDA v. Alliance for Hippocratic Medicine, which the Court dismissed unanimously on standing grounds, this round involves a state plaintiff, a different legal theory, and an appellate court willing to override the FDA's scientific conclusions [6][7].

The Scale of What's at Stake

Medication abortion has grown from 28% of all U.S. abortions in 2011 to 65% in 2023, driven in large part by expanded access through telehealth and mail-order pharmacies [8][9].

Source: Guttmacher Institute / KFF

Data as of Oct 1, 2025CSV

The telehealth share of that total has itself surged, climbing from 5% in the second quarter of 2022 to 27% by mid-2025, according to the Society of Family Planning's #WeCount tracking project [10].

Source: Society of Family Planning #WeCount

Data as of Dec 18, 2025CSV

In raw numbers, that growth is substantial. The monthly average number of abortions inside the medical system rose from 79,600 in 2022 to 98,800 per month in the first half of 2025 [10]. By June 2025, telehealth providers operating under state shield laws were serving 14,770 women per month who lived in states with bans or restrictions — a 61% increase from the prior year [10].

The 5th Circuit's order does not merely affect states with abortion bans. Because it blocks the FDA's nationwide mail-dispensing authorization, the ruling applies even in states where abortion is legal, forcing patients who previously received mifepristone by mail to obtain it in person at a certified facility [2][3].

How the Legal Mechanism Works

Louisiana filed its challenge under the Administrative Procedure Act in October 2025, arguing that the FDA's 2021 and 2023 decisions to drop the in-person dispensing requirement were arbitrary and not supported by adequate data [11]. The state was joined by a woman who alleged she was coerced into taking abortion pills shipped from out of state [12].

The legal theory rests on several pillars. First, Louisiana argues that remote dispensing effectively "opened the door for mifepristone to be remotely prescribed to Louisiana women" in violation of the state's near-total abortion ban, creating a direct injury to state sovereignty [5][11]. Second, the state claims financial harm through Medicaid costs tied to emergency care for complications, documenting roughly $92,000 in costs from two women who suffered complications from out-of-state mifepristone [12]. Third, the state and allied parties have invoked the Comstock Act — an 1873 anti-obscenity law that originally prohibited mailing any "instrument, substance, drug, medicine, or thing" that could be used in an abortion — arguing that mail distribution of mifepristone violates this still-extant federal statute [13][14].

The 5th Circuit accepted these arguments and rejected the Trump administration's position that Louisiana's lawsuit suffered procedural defects. The court found that Louisiana has both a "sovereign interest in enforcing its abortion laws" and a financial interest in Medicaid expenditures sufficient to establish standing [11][5].

This standing ruling is itself a significant development. In 2024, the Supreme Court held unanimously that individual doctors opposed to abortion lacked standing to challenge the FDA's mifepristone rules, with Justice Kavanaugh writing that their "sincere legal, moral, ideological, and policy objections" did not amount to the concrete harm required for federal jurisdiction [6]. The 5th Circuit distinguished the current case by treating the state of Louisiana as a different kind of plaintiff — one whose sovereign and financial injuries give it a legal foothold that private plaintiffs lacked.

The FDA's Safety Record Under Scrutiny

Central to the dispute is a factual disagreement about whether remote dispensing of mifepristone is safe.

The FDA's position, developed over more than two decades of post-market surveillance, is that it is. The agency approved mifepristone in 2000 and initially imposed strict requirements: only certified physicians could prescribe it, and patients had to receive it in person [15]. Those restrictions were loosened in 2016 and again during the COVID-19 pandemic. In 2023, the Biden administration made the changes permanent, citing the drug's established safety profile [3][15].

The published data supports the FDA's conclusion. Mifepristone terminates pregnancy 99.6% of the time, with a major complication rate of 0.4% and a mortality rate of less than 0.001% (0.00064%) [8][16]. Over the past two decades, more than 2.75 million people have used the drug, with 24 reported deaths — a risk of less than one in 100,000 [16]. A peer-reviewed study of 54,911 medication abortions reimbursed through California's Medicaid program found major complication rates of 0.31%, comparable to clinical trial rates [17]. A separate study of mail-order pharmacy dispensing after in-person screening found serious adverse events in 0.6% of cases, similar to the 0.3% rate observed with in-person dispensing [17].

For context, those complication rates are lower than those associated with many commonly prescribed medications that face no equivalent distribution restrictions. Penicillin carries an anaphylaxis risk of roughly 0.01-0.05%, and opioid painkillers — routinely mailed to patients — carry far higher rates of adverse events, dependency, and death [16][8].

Louisiana's counterargument targets the evidentiary foundation itself. The state argues that the FDA previously eliminated the requirement that mifepristone's adverse events be reported to its safety database, then cited the resulting absence of reports as evidence the drug was safe to dispense remotely [12]. This procedural circularity, Louisiana contends, means the safety data the FDA relies on is systematically incomplete. The state documented what it described as nearly 1,000 illegal abortions per month facilitated by the mail-access regulation [12].

The Strongest Case for Restricting Mail Access

The plaintiffs' position is not solely procedural. Their strongest substantive argument centers on the specific risks of remote prescribing without in-person screening.

Ectopic pregnancies — in which a fertilized egg implants outside the uterus — cannot be treated with mifepristone and can become life-threatening if undiagnosed. In-person visits historically included ultrasound screening to rule out this condition. Plaintiffs argue that telehealth consultations cannot reliably detect ectopic pregnancies, creating a category of risk unique to remote dispensing [12][18].

The FDA's response is that its revised protocol accounts for this: patients are screened for ectopic pregnancy risk factors during telehealth consultations and instructed to seek emergency care for specific warning symptoms. The agency concluded that this approach, combined with the low baseline rate of ectopic pregnancy, does not justify requiring in-person visits for all patients [15].

No peer-reviewed study has found a statistically significant increase in ectopic pregnancy complications specifically attributable to telehealth prescribing of mifepristone. A 2024 study published in Nature Medicine examining the effectiveness and safety of telehealth medication abortion found outcomes comparable to in-person care [19]. However, the absence of a mandatory adverse event reporting system — the very gap Louisiana highlights — makes it difficult to say with certainty that no increased risk exists.

Academic Research and the Scientific Debate

The volume of academic research on mifepristone and medication abortion has grown substantially over the past decade. According to OpenAlex data, publications on the topic peaked at 436 papers in 2023 — the year the FDA finalized its mail-access rules — and have remained elevated since, with 346 papers in 2025 [20].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Guttmacher Institute has characterized some of the evidence cited by mifepristone opponents as methodologically flawed, pointing to studies that relied on emergency room billing codes rather than confirmed diagnoses to estimate complication rates [21]. At the same time, the institute acknowledges that comprehensive post-market surveillance data remains limited because the FDA relaxed its adverse event reporting requirements in 2016 [21].

Who Profits, Who Pays

The manufacturers filing the emergency appeal have clear financial stakes. Danco Laboratories is a single-product company: Mifeprex is its only drug [22]. GenBioPro, the sole U.S. generic manufacturer, has stated that mifepristone and misoprostol sales "represent the majority of the company's revenue" [23]. GenBioPro's products now account for approximately two-thirds of the roughly 500,000 medicated abortions performed annually in the United States [22][23].

Neither company publicly discloses revenue figures. The median self-pay price for medication abortion was $560 as of 2020, though telehealth providers have driven costs down to $150 or less through sliding-scale pricing [8]. At an estimated 500,000 medication abortions per year, the total U.S. market is likely in the range of several hundred million dollars annually.

Critics of the manufacturers' framing argue that the "chaos" language in their court filings reflects commercial anxiety as much as concern for patient welfare [23]. If brand-name mail access were curtailed, would alternative suppliers fill the gap? Compounding pharmacies — which can produce custom drug formulations — are not currently authorized to compound mifepristone under the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which restricts distribution to certified providers [15]. A mail ban would not create a supply shortage of the drug itself but would require patients to obtain it in person, fundamentally altering the distribution model on which both companies' current business depends.

That said, the manufacturers' financial interests and patient access interests are not mutually exclusive. The reason mail dispensing became commercially viable is that patients wanted it — and the FDA concluded it was safe.

The Geography of Access

The 5th Circuit's ruling falls hardest on patients in states where in-clinic alternatives are already scarce. As of April 2026, 13 states enforce total abortion bans [21]. In those states, patients already relied heavily on telehealth providers operating under shield laws in states like New York, Massachusetts, and Colorado — providers who wrote prescriptions and mailed pills across state lines to an estimated 14,770 women per month by mid-2025 [10].

But the ruling also affects patients in states where abortion is legal. Thirteen states that permit abortion still impose restrictions requiring at least one in-person clinic visit, effectively precluding full telehealth medication abortion even before the 5th Circuit's order [8]. In rural areas of states like Montana, Wyoming, and the Dakotas, the nearest abortion-providing clinic can be hundreds of miles away. ACLU attorney Julia Kaye noted that "when telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most" [2].

The cost burden is not evenly distributed. Virtual consultations with mail delivery typically cost $150 or less [8]. An in-person visit, factoring in travel, lodging, childcare, and lost wages, can multiply that cost several times over — a barrier that falls disproportionately on low-income patients, who are already more likely to seek abortion care [8].

GenBioPro's emergency filing underscored the immediate practical impact: "Today, patients who planned to pick up a mifepristone prescription at their local pharmacy may no longer be able to do so" [2].

The Precedent Problem

Legal scholars have identified what may be the most consequential dimension of Louisiana v. FDA: the precedent it sets for future challenges to FDA drug approvals.

If the 5th Circuit's reasoning holds — that a state can establish standing by claiming downstream Medicaid costs and sovereignty injuries from a federal agency's drug-distribution decisions — the door opens for similar challenges to other medications. Former FDA commissioners argued in an amicus brief in the earlier Alliance for Hippocratic Medicine case that such a precedent could allow drug companies to challenge competitors' FDA approvals, or "organizations representing patients who experience rare adverse events could challenge FDA's risk-benefit analyses and attempt to bar access to safe and effective remedies for others who need them" [24].

Lawrence Gostin, faculty director of Georgetown University's O'Neill Institute for National and Global Health Law, warned that the approach could "open the floodgates" to lawsuits targeting everything from contraceptives to vaccines to gender-affirming care [24]. Dr. Amanda Banks observed that "this case is about mifepristone right now — it's about one medicine, but it really could be any medicine" [24].

GenBioPro made the point directly in its filing: the 5th Circuit's standing analysis "would allow States to challenge virtually any agency action whenever they allege downstream costs or interference with state policy" [5].

The question the Supreme Court must now consider is whether a limiting principle exists. In 2024, the standing doctrine served that function — the Court found that private plaintiffs simply hadn't demonstrated concrete injury. But with a state as plaintiff, the injury calculus changes. Every state incurs Medicaid costs. Every state has policies that can be characterized as "undermined" by federal regulatory decisions. If that is enough for standing, the number of potential challenges to FDA authority becomes difficult to bound.

What Happens Next

The emergency application is now before the Supreme Court. Danco has asked the justices to stay the 5th Circuit's order while the underlying case proceeds — meaning, to restore mail access temporarily. The Court could act quickly, potentially within days, or could request briefing from Louisiana and the federal government before deciding [4][5].

The Trump administration's posture adds complexity. While the administration argued in the 5th Circuit that Louisiana's case had procedural defects, it did not defend the underlying FDA policy with the vigor that the Biden administration would have. The Solicitor General's office has not yet indicated whether it will support or oppose the emergency stay at the Supreme Court level [11][5].

If the Court grants the stay, mail access resumes while the case works through the lower courts — a process that could take a year or more. If it denies the stay, the in-person requirement remains in effect nationwide, and the practical impact on hundreds of thousands of patients begins immediately.

Either way, the Court's decision will signal how far it is willing to let states go in challenging the FDA's regulatory authority — a question with implications that reach well beyond mifepristone, and well beyond abortion.